Introduction

▼
Ketorolac is a pyrrolizine carboxylic acid derivative, chemically, ( ± )-5-benzoyl-2, 3-dihydro-1 H-pyrrolizine-1-carboxylic acid. It is a non steroidal antiinfl ammatory drug and is used principally for its analgesic activity [ 1 ] in short-term ( < 5 days) management of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. It is a non selective cyclooxygenase (COX) inhibitor [ 2 , 3 ] , which leads to decreased formation of precursors of prostaglandins and thromboxanes from arachidonic acid [ 4 , 5 ] . Animal studies have shown that the pharmacological activity of Ketorolac resides in the (−)-S-enantiomer and that the ( + )-R-enantiomer is pharmacologically inactive [ 6 ] . The enantiomers of Ketorolac are depicted in • ▶ Fig. 1 .
The pharmacokinetics of Ketorolac have been documented in humans [ 7 -14 ] and animals include dogs [ 15 ] , rats [ 16 ] , calves [ 17 ] , rabbits [ 18 ] , goats [ 19 ] , sheep [ 20 ] . The purpose of the present work was to understand the enantioselective pharmacokinetic behavior of of Ketorolac after administration of single I.V dose of recemic Ketorolac in rats using compartmental and non-compartmental analysis.
Ketorolac, a commonly used anti-inflamatory and analgesic agent, was studied in male wistar rats. The plasma samples were analysed using chiral AGP column with UV detection. The experimental data was analysed for probable fi t in the compartmental and non-compartmental models using WinNolin software. The data of (+)-R-Ketorolac and (−)-S-Ketorolac was found to fi t into the compartmental as well as non compartmental model. There was a difference between the plasma concentrations of ( + )-R-Ketorolac and (−)-S-Ketorolac; the plasma concentrations of ( + )-R-Ketorolac were higher than those of (−)-S-Ketorolac throughout the time course of the study. The area under the curve (AUC) of time vs. concentration profi le of ( + )-R-Ketorolac was found to be higher than (−)-S-Ketorolac. Volume of distribution and clearance was found to be higher for (−)-S-Ketorolac. ments, Singapore) was used for measuring pH of all buff er systems. Membrane fi lters of 0.22 μm (Millipore, USA) were used for fi ltration of aqueous phase used in the mobile phase system.
Animals
Healthy male wistar rats weighing between 180-220 g were selected for intravenous pharmacokinetic study of Ketorolac in plasma. The food for the animals withheld before 12 h of the study but animals had free access to drinking water. All experimental protocols were approved by the Institutional Animal Ethics Committee (IAEC).
Collection of blood and separation of plasma
Blood was collected from retro-orbital plexus of wistar rats. Clear supernatant plasma was separated from blood after the centrifugation at 3 500 rpm, 4 °C, for 10 min. Samples were kept at − 20 °C till further analysis.
Extraction technique
A simple, solid phase extraction method was followed for extraction of ketorolac from wistar rat plasma. 500 μL of plasma sample was pipette into an ependroff tube and 200 μL of mobile phase, 100 μL 0 f 5 % v/v formic acid was added to it and vortexed for 2-3 min and the drug was eluted by methanol using solid phase extraction (using OASIS HLB).The eluates were evaporated to dryness at 50 °C under a gentle nitrogen gas (N 2) . The dry residue was re-constituted in 500 μL of mobile phase, transferred to a sample-loading vial and 50 μL of sample was injected into the HPLC system.
Chromatographic Conditions
A chiral-AGP column (100 × 4.0 mm I.D., particle size 5 μ, Chromtech Ltd, Sweden) was used for the study. The isocratic mobile phase consisted of an aqueous phase (100 mM sodium di-hydrogenphosphate pH 7.4) and isopropylalchol (96: 4 v/v).
Buff er was fi ltered through 0.22 μm Millipore membrane fi lter. The HPLC system was stabilized for 2 h at 1 mL min 
Pharmacokinetic study
Ketorolac formulation for intravenous (I.V) bolus administration was prepared by dissolving the drug in saline solution just before the commencement of the study. Formulation was administered through tail vein in male wistar rats. Blood samples were drawn at 2, 4, 8, 16, 32, 60, 120, 240, 480 min post dose in microfuge tube pretreated with EDTA (Ethylene Diamine Tetra Acetic acid). All samples were processed according to the procedure described earlier and analyzed using the validated HPLC method. Various pharmacokinetic parameters were calculated from measured Ketorolac plasma concentrations vs. time profi les after I.V bolus administration using non-compartmental model and compartmental models in WinNonlin Professional software (Version 2.1, Pharsight Corporation, USA). The Individual plasma concentrations vs. time plots were constructed ( • ▶ Fig. 3 ). The plasma concentration-time profi les of (−)-S-Ketorolac and ( + )-R-Ketorolac after I.V administration of 3.2 mg/kg of ketorolac to rats, the area under the curve (AUC), the volume of distribution (V d ), the total drug clearance (CL) and the terminal half-life (t 1/2 ) were determined. AUC was estimated by the trapezoidal rule and extrapolated to infi nity by multiplying the last detectable concentration by the time constant of the terminal concentration decay phase. Volume of distribution was obtained by dividing the dose by the extrapolated concentration corresponding to time zero. Clearance was estimated by dividing the dose by AUC. Half-life was estimated from the slope obtained by linear regression of the terminal phase of semi-logarithmic time versus concentration plots [ 21 ] . 
Statistical considerations
Statistical analysis of pharmacokinetic data was done using the software Graph Pad Prism ver.5. The data is presented as the mean ± SE at the 95 % confi dence interval. Paired t-test was used to compare the pharmacokinetic parameters between ( + )-RKetorolac and S-Ketorolac.
Results and Discussion
▼
Plasma concentrations of ( + )-R-Ketorolac exceeded those of (−)-S-Ketorolac throughout the time course. As the AUC 0-∞ of ( + )-R-Ketorolac was signifi cantly higher than that of (−)-SKetorolac, the total body clearance (CL) of (−)-S-Ketorolac was signifi cantly larger than that of R-ketorolac. The plasma concentrations of ( + )-R-Ketorolac decreased more slowly than those of S-ketorolac. The elimination half-life (t 1/2 ) of ( + )-R-Ketorolac was signifi cantly longer than that of (−)-S-Ketorolac. The pharmacokinetic parameters of each enantiomer and their paired t-test probability values of the diff erence between each enantiomer are given in • ▶ Table 1 for one compartmental, • ▶ Table 2 for the 2 compartmental and • ▶ Table 3 for the non-compartmental model. A signifi cant enantiomeric diff erence in pharmacokinetic parameters was observed for V d, CL, Cmax, and AUC in all models (i. e., compartmental as well as noncompartmantal). The pharmacokinetic parameters for pharmacologically active (−)-(S)-enantiomer including V d, CL were approximately twice and Cmax, AUC were approximately half, than that of its optical antipode based on a Mean ± SE (P < 0.05) (S)/(R) ratio of Cmax 0.553 ± 0.008, V d 1.883 ± 0.125 CL 2.159 ± 0.034 and AUC 0.4609 ± 0.004. The statistically signifi cant diff erence in the elimination rate constant and elimination half life was observed in one-compartmental model but not in 2 compartmental model and non compartmental model.
Conclusions
▼
The objective of present I.V bolus study is to clarify the fundamental pharmacokinetic properties of both S and R-enantiomers. The I.V dose of 3.2 mg/kg pharmacokinetic study shows that (−)-S-Ketorolac and ( + )-R-Ketorolac follows 2-compartmental as well as non-compartmental models. The AUC 0-∞ of ( + )-RKetorolac was higher than that of (−)-S-Ketorolac. Volume of distribution and clearance was found to be higher for (−)-SKetorolac. These fi ndings indicated that the pharmacokinetics of Ketorolac in rats were stereo-selective.
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